Drug Trial Radar · NCT06655883
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Oct 9, 2025
Primary completion
Jun 24, 2027
Study completion Jun 24, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
Conditions
- Insomnia
Interventions
SuvorexantDrug
Oral Tablet
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Sleep Time at Week 8Time frame: Baseline and Week 8
- Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 10 weeks
- Number of Participants Who Experience One or More Serious Adverse Events (SAEs)Time frame: Up to approximately 10 weeks
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 8 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Cenexel CNS ( Site 2012)
Garden Grove, California · Recruiting
Yale University School of Medicine ( Site 1003)
New Haven, Connecticut · Recruiting
Bradenton Research Center ( Site 2021)
Bradenton, Florida · Recruiting
CenExel iResearch, LLC ( Site 2010)
Savannah, Georgia · Recruiting
Johns Hopkins University ( Site 1001)
Baltimore, Maryland · Recruiting
Hassman Research Institute Marlton Site ( Site 2005)
Marlton, New Jersey · Recruiting
The Rivus Wellness & Research Institute ( Site 2014)
Oklahoma City, Oklahoma · Recruiting
Penn Medicine University of Pennsylvania Health System- Center for Studies of Addiction ( Site 1006)
Philadelphia, Pennsylvania · Recruiting
Butler Hospital ( Site 1002)
Providence, Rhode Island · Recruiting
Medical University of South Carolina ( Site 1005)
Charleston, South Carolina · Recruiting
Adams Clinical Dallas ( Site 2007)
DeSoto, Texas · Recruiting
Memorial Hermann Village ( Site 2001)
Houston, Texas · Recruiting
VCU Institute for Drug and Alcohol Studies ( Site 1004)
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.